Evotec Partners With Navan To Replace Fragmented Travel And Expense Tools With One Automated Global Platform

Evotec Subsidiary Just Biologics Moves JST-018 Orthopoxvirus Antibodies Into First-In-Human Phase 1 Study For Biodefense

First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

Evotec shares are trading lower after the company reported worse-than-expected Q2 financial results.

Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate

Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same

Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results

U.S. stocks fell Thursday as the Dow dropped 300+ points; Macy’s slid on weak guidance, while oil rose and producer prices accelerated.

Citizens Reiterates Market Outperform on Navan, Maintains $38 Price Target

Citizens analyst Patrick Walravens reiterates Navan (NASDAQ:NAVN) with a Market Outperform and maintains $38 price target.